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Extracts from the leaves and flowers of Crataegus spp. (i.e., hawthorn species) have 
been traditionally used with documented preclinical and clinical activities in cardiovascular 
medicine. Based on reported positive effects on heart muscle after ischemic injury and 
the overall cardioprotective profile, the present study addressed potential contributions of 
Crataegus extracts to cardiopoietic differentiation from stem cells. The quantified Crataegus 
extract WS®1442 stimulated cardiomyogenesis from murine and human embryonic 
stem cells (ESCs). Mechanistically, this effect was found to be induced by promoting 
differentiation of cardiovascular progenitor cell populations but not by proliferation. 
Bioassay-guided fractionation, phytochemical and analytical profiling suggested high-
molecular weight ingredients as the active principle with at least part of the activity due 
to oligomeric procyanidines (OPCs) with a degree of polymerization between 3 and 6 
(DP3–6). Transcriptome profiling in mESCs suggested two main, plausible mechanisms: 
These were early, stress-associated cellular events along with the modulation of distinct 
developmental pathways, including the upregulation of brain-derived neurotrophic factor 
(BDNF) and retinoic acid as well as the inhibition of transforming growth factor β/bone 
morphogenetic protein (TGFβ/BMP) and fibroblast growth factor (FGF) signaling. In 
addition, WS®1442 stimulated angiogenesis ex vivo in Sca-1+ progenitor cells from adult 
mice hearts. These in vitro data provide evidence for a differentiation promoting activity 
of WS®1442 on distinct cardiovascular stem/progenitor cells that could be valuable for 
therapeutic heart regeneration after myocardial infarction. However, the in vivo relevance 
of this new pharmacological activity of Crataegus spp. remains to be investigated and 
active ingredients from bioactive fractions will have to be further characterized.
Keywords: crataegus spp., regenerative medicine, stem cells, angiogenesis, oligomeric proanthocyanidines, 
cardiomyogenic differentiation, bioassay-guided fractionation
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iNTrODUCTiON
Natural products frequently serve as an inspiration and attractive 
starting point for the development of novel pharmacological agents 
(Newman and Cragg, 2012). In the present study, the aim was to 
investigate a complex plant-derived extract with documented 
use in cardiovascular medicine and which could be promising in 
the context of cardiac regeneration after myocardial infarction. 
Quantified extracts of the flowers and leaves of hawthorn (Crataegus 
spp.) have been used since decades for the adjuvant treatment 
of heart failure (i.e., NYHA I and II) (Koch and Malek, 2011; 
European Medicines Agency, 2016; European Pharmacopoeia, 
2017). Based on this tradition and the documented safety they 
have been classified as “traditional herbal medicinal product” by 
the Committee for Herbal Medicinal Products of the European 
Medicines Agency (European Medicines Agency, 2016).
One of the most comprehensively studied hawthorn extracts 
is WS®1442 (Crataegutt®). Although no significant effect on 
mortality have been shown in a large clinical trial involving this 
extract (SPICE study, 2008) (Holubarsch et al., 2008), data from 
this and other in vitro and in vivo studies in humans and animals 
are indicating significant cardiovascular activity (Koch and 
Malek, 2011; European Pharmacopoeia, 2017). Besides efficacy 
in secondary endpoints, the large scale, long-term mortality 
trial did show that the use of WS®1442 is safe in patients 
receiving optimal medication for heart failure (Holubarsch 
et  al., 2008). Crataegus extracts exhibit a pronounced 
pleiotropic pharmacological profile and, particularly regarding 
heart muscle physiology, several interesting activities have been 
reported: Crataegus extracts have a positive inotropic effect via 
a cAMP-independent mechanism. Protective effects within rat 
models of ischemic reperfusion after myocardial infarction 
have been described, which lead to a reduced spreading of the 
infarction area (Veveris et al., 2004). Such effects were mostly 
attributed to an unspecific anti-oxidant activity of oligomeric 
procyanidines (OPCs), but also specific signaling pathways 
involving the serine-threonine kinase Akt and the hypoxia-
inducible factor 1 (HIF-1) have been suggested to play a role. 
In the context of cardiac hypertrophy, it has been shown that 
WS®1442 inhibits the phosphatase activity of calcineurin, an 
important trigger of cardiomyocyte growth (Koch and Spörl-
Aich, 2006). Several other activities have been reported for 
hawthorn extracts, such as a decrease in the expression of 
atrial natriuretic factors (ANF) and fibronectin in rat models 
of hypertension and cardiac hypertrophy. Many mechanistic 
studies were performed in the context of vascular (patho)
physiology since WS®1442 exhibits positive effects on the 
vascular endothelium. In this regard, an increased availability 
of nitric oxide (NO) has been shown along with the release of 
reactive oxygen species (ROS) which again trigger Src/PI3K/Akt 
signaling and inhibit PDGFβ-mediated signaling. In addition, 
vascular effects of WS®1442 were linked to the inhibition of 
Ca2+/PKC/RhoA-signaling and activation of cAMP/Rap1/Rac1 
signaling (Furst et al., 2010; Bubik et al., 2011).
Based on the large number of positive effects on the 
myocardium after ischemic injury and the overall cardiovascular 
profile, we aimed at studying whether also mechanisms of 
cellular differentiation and regeneration could possibly play a 
role for hawthorn extract WS®1442. For this purpose, cardiac 
differentiation assays in murine and human embryonic stem cells 
as well as Sca-1+ progenitor cells isolated from murine hearts 
were used. Our results provide evidence for a differentiation 
promoting activity of WS®1442 that might be valuable for 
therapeutic heart regeneration after myocardial infarction.
MATEriAlS AND METHODS
Fractionation and Phytochemical 
Characterization of Crataegus Extract 
WS®1442
WS®1442 is a dry ethanolic (45% w/w, drug-to-solvent ratio 
4–6.6:1) extract from hawthorn leaves with flowers according 
to the European Pharmacopoeia (European Medicines Agency, 
2016), and was kindly provided by Dr. Willmar Schwabe GmbH 
& Co. KG. According to the European Pharmacopoeia, extracts 
from the hawthorn leaf and flower are derived from whole or 
cut, dried flower-bearing branches of Crataegus monogyna 
Jacq., C. laevigata (Poir.) DC. (syn. C. oxyacanthoides Thuill.; C. 
oxyacantha auct.) or their hybrids or, more rarely, other European 
Crataegus species including C. pentagyna Waldst. et Kit. ex 
Willd., C. nigra Waldst. et Kit., and C. azarolus L. Following the 
protocol by Vennat et al. (1992), 500 g of WS®1442 (Ch. 289 
N001) were fractionated using Sephadex LH-20 column (22.5cm 
× 65cm; Pharmacia) chromatography by sequential elution with: 
75 L demineralized water, 70 L ethanol 95% (v/v), 70 L methanol 
100%, and 50 L acetone-water 70% (v/v). The volume of each 
individual eluent was collected in a single fraction to give the 
water fraction (= “water eluate,” yield 285 g), the ethanol fraction 
(= “EtOH eluate,” yield 59 g), the methanol fraction (= “MeOH 
eluate,” yield 68 g), and the acetone fraction (= “acetone eluate,” 
yield 29 g), respectively. According to a procedure described by 
Chatterjee et al. (1997), 400 g of WS®1442 (Ch. 289 N001) were 
partitioned twice between ethyl acetate and water. The combined 
ethyl acetate phases were concentrated and dried to give 42  g 
of fraction “ethylacetate.” From the remaining water phase, 
residual ethyl acetate was removed. Then ethanol was added to 
give a 40% ethanolic solution which was ultrafiltrated through 
a S1Y3 filter (Amicon, 3000 Dalton) (= “ultrafiltrate” fraction). 
The ultrafiltrate was concentrated and freeze-dried to give 264 g 
of fraction B. The retentate was washed off the filter using 60% 
(m/m) ethanol, then concentrated and freeze-dried to yield 75 g 
of the “ultraretentate” fraction.
Flavonoid quantification was performed according to the 
respective monograph of Ph.Eur. Ed. 9 (2017) and % flavones 
Abbreviations: ANF, atrial natriuretic factors; BDNF, brain-derived neurotrophic 
factor; BMP, bone morphogenetic protein; cTnT, cardiac Troponin T; DP, 
degree of polymerization; ESCs, embryonic stem cells (murine, mESCs; human, 
hESCs); EtOH eluate, ethanol eluate; FGF, fibroblast growth factor; MeOH eluate, 
methanol eluate; MHC, myosin heavy chain; OPCs, oligomeric procyanidines; 
PDGFβ, platelet-derived growth factor subunit β; RA, retinoic acid; Raldh2, 
retinaldehyde dehydrogenase 2; ROS, reactive oxygen species; Sca-1, stem cells 
antigen-1; Sca-PC, Sca-1+ progenitor cells; TGFβ, transforming growth factor β; 
WT, wild-type.
Frontiers in Pharmacology | www.frontiersin.org November 2019 | Volume 10 | Article 1357
WS®1442 Stimulates Cardiovascular Stem CellsHalver et al.
3
were calculated as hyperoside (European Medicines Agency, 
2016). OPCs were determined with Folin-Ciocalteu reagent in 
a modified manner as described by Holzl and Strauch (1977), 
using (-)-epicatechin as standard (Holzl and Strauch, 1977).
lC-MS- and lC-FD-Analytics
All samples (WS®1442 and fractions/eluates) were dissolved in 
acetonitrile-water (1:1, v/v), centrifuged, and then diluted to a 
final concentration of 10 mg/ml with the same solvent.
LC-MS methods
1) For the analysis of monomeric procyanidins, flavonoids, and 
other low molecular weight Crataegus ingredients, separation was 
performed on a Dionex Ultimate 3000 RS Liquid Chromatography 
System over a Dionex Acclaim PAII column (2.1 × 100 mm, 2.2 
µm) with a binary gradient (A: water with 0.1% formic acid; B: 
acetonitrile with 0.1% formic acid) at 0.4 ml/min. 0 to 0.4 min: 
isocratic at 5% B; 0.4 to 9.9 min: linear from 5 to 100% B; 9.9 to 15.0 
min: isocratic at 100% B; 15.0 to 15.1 min: linear from 100 to 5% B; 
15.1 to 20.0 min: isocratic at 5% B. The injection volume was 2 µl. 
Eluted compounds were detected using a Dionex Ultimate DAD-
3000 RS over a wavelength range of 200–400 nm and a Bruker 
Daltonics micrOTOF-QII time-of-flight mass spectrometer 
equipped with an Apollo electrospray ionization source in 
negative mode at 3 Hz over a mass range of m/z 50–1,500 using the 
following instrument settings: nebulizer gas nitrogen, 4 bar; dry 
gas nitrogen, 9 L/min, 200°C; capillary voltage 3,500 V; end plate 
offset -500 V; low mass 100 m/z; transfer time 100 µs, prepulse 
storage 6 µs; collision cell: 40 eV, isolation width 5, collision cell RF 
130 Vpp. Internal dataset calibration (HPC mode) was performed 
for each analysis using the mass spectrum of a 10 mM solution of 
sodium formate in 50% isopropanol that was infused during LC 
reequilibration using a divert valve equipped with a 20 µl sample 
loop. 2) For the analysis of OPCs with DP > 1, the gradient was 
modified as follows: 0 to 0.4 min: isocratic at 10% B; 0.4 to 9.0 min: 
linear from 10 to 40% B; 9.0 to 9.1 min: linear from 40 to 100% B; 
9.1 to 15.0 min: isocratic at 100% B; 15.0 to 15.1min: linear from 
100 to 10% B; 15.1 to 20.0 min: isocratic at 10% B. The MS settings 
were modified as follows: mass range m/z 300–3,000; low mass 300 
m/z; transfer time 140 µs; prepulse storage 15 µs, collision cell RF 
600 Vpp. All other settings as stated above.
For OPCs, peaks were detected by base peak chromatograms 
of each deprotonated molecule’s most abundant isotopic signal 
(according to isotope pattern simulation) at its most abundant 
charge (empirical: DP1–4 z = 1, DP5–8 z = 2, DP > 8 z = 3) with 
a width of m/z ± 0.01. Peak heights were taken as signal size. 
Other compounds were detected using the Dissect Compounds 
algorithm of DataAnalysis 4.1 (Bruker Daltonics) and processed 
using an in-house VBA script. The signal intensity of each 
deprotonated molecule (z = 1) was used as signal size.
LC-FD method
Separation was performed on a Waters H-Class UHPLC system 
by an Acquity® UPLC BEH200 SEC (1.7 µm, 4.6 × 150 mm) 
column with a binary gradient (A: acetonitrile: acetic acid [98: 
2]; B: methanol: water: acetic acid [86: 12: 2]) at 1.0 ml/min. 0 to 
6.18 min: linear from 0 to 35% B; 6.18 to 7.75 min: linear from 35 
to 40% B; 7.75 to 9 min: isocratic at 40% B; 9 to 10.5 min: 40 to 
100% B; 10.5 to 13 min: isocratic at 100% B; 13 to 15 min: 100 to 
0% B; 15 to 18 min: isocratic at 0% B. The injection volume was 
5 µl. Eluted compounds were detected with a fluorescence 
detector with λ(ex) 280 nm and λ(em) 316 nm.
Cell Culture
Cardiac Differentiation of Embryonic Stem Cells (ESCs)
mESC culture, differentiation, and automated high content 
image analysis 
CGR8 mESC (ECACC catalog 07032901) is a germ-line 
competent cell line that was established from the inner cell 
mass of a 3.5 day male pre-implantation mouse embryo (Mus 
musculus, strain 129). CGR8 and CGR8-Myh6-GFP mESCs 
were grown under feeder-free conditions as monolayers and 
maintained in DMEM (Gibco®) supplemented with 10% fetal 
bovine serum (FBS, PAN Biotech), 1% L-glutamine (Gibco®), 1% 
non-essential amino acids (Gibco®), 1% penicillin/streptomycin 
(Gibco®), 0.1 mM 2-mercaptoethanol (Gibco®), and 15 ng/ml 
murine LIF (Dortmund Protein Facility). Cells were cultured on 
0.1% gelatin-coated 6-well plates (at 37°C, 5% CO2) and passaged 
after 2–3 days when confluency reached 60–70% to preserve 
the undifferentiated phenotype. A modified protocol was used 
for mESC cardiac differentiation (Schade et al., 2012; Willems 
et al., 2012). Briefly, cells were trypsinized and cultured in 
differentiation media (at 37°C, 5% CO2) on 0.1% gelatin-coated 
384-well plates at a density of 500 cells per 50 µl differentiation 
media per well (= d0). The differentiation medium was composed 
of DMEM (Gibco®) supplemented with 10% FBS (PAN Biotech), 
1% L-glutamine (Gibco®), 1% non-essential amino acids 
(Gibco®), 1% penicillin/streptomycin (Gibco®), and 0.1 mM 
2-mercaptoethanol (Gibco®). At day 3 of differentiation (= d3), 
medium was added to 75 µl assay volume. Cells were treated with 
indicated compounds/extract/fractions or DMSO from day 4 to 
day 6 and incubated until day 11. During this time, the medium 
was replaced every 48–72 h. At day 11 of differentiation (= d11) 
cells were fixed in 4% paraformaldehyde and incubated with 
DAPI for nucleic acid staining. Myh6-GFP positive cells were 
imaged on a MicroXL System (Molecular Devices) and GFP 
levels from images were quantified with MetaXpress Software, 
using a multi-wavelength scoring algorithm (Molecular Devices).
hESC culture, differentiation and automated high content 
image analysis
A directed differentiation protocol and image-based quantification 
of cardiogenesis was performed in H9-hESCs carrying an 
MYH6-mCherry reporter as described previously (Willems et 
al., 2011; Lanier et al., 2012). H9 is a human (male) blastocyst-
derived, pluripotent embryonic stem cell line provided by the 
Wicell Research Institute (Madison, USA). Crataegutt® (liquid 
formulation) was prepared by dilution with PBS to the desired 
concentrations, followed by sterile filtration. After replating 
differentiated hESCs into 384-well plates on day 4 of differentiation, 
cells were treated from day 5–9 with the dilutions. Subsequent cell 
culture and image analysis was done according to the previously 
described protocols (Willems et al., 2011; Lanier et al., 2012).
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Immunocytochemistry and confocal microscopy
On d11, paraformaldehyde-fixed and DAPI-stained cells were 
permeabilized with 0.25% Triton X-100 in PBS for 30 min at RT. 
After blocking with 10% FBS in PBS, cells were incubated with 
mouse cardiac Troponin T antibody (Thermo Scientific) or mouse 
cardiac myosin heavy chain antibody (eBioscience) at dilutions 
between 1:100–1:200. After incubation at 4°C overnight, cells 
were washed several times with PBS and then incubated with the 
corresponding secondary antibody (1:1000) for 4 h at RT. Images 
of PBS-washed cells were obtained using a Molecular Devices 
MicroXL System (10x) and Leica SP5 confocal microscope (20x).
Flow cytometry
Differentiated mESC cultures were trypsinized and dissociated 
into single cell suspensions pooling 16–48 wells of the same 
condition in 384-well-plates. After centrifugation, cells were fixed 
in 4% paraformaldehyde and incubated for 10 min at RT. Fixed 
cells were centrifuged and incubated with mouse anti-myosin 
heavy chain eFluor 660® (eBioscience, 1:100 in 0.25% saponine/2% 
FBS in PBS) for 1 h at RT in the dark. Following washes with 
0.25% saponine/2% FBS in PBS, cells were resuspended in 500 µl 
0.25% saponine/2% FBS in PBS and analyzed on a BD LSRII Aria 
instrument. FlowJo software was used for data analysis.
Cell viability and proliferation assays
Cell viability was determined with the CytoScan™ WST-1 
Cell Cytotoxicity Assay (G-Biosciences) according to the 
manufacturer’s instructions. Assay dye solution was directly 
added to the cells in the culture medium at a final concentration of 
10%. After incubation for 4 h at 37°C, absorbance was measured 
using a microplate reader (Tecan Infinite M1000) at 420–480 
nm. Following the general immunostaining protocol (see above), 
proliferation status of the cells was determined by image-based 
quantification (Image Xpress, Molecular Devices, see above) of 
total cell number (DAPI count) and the number of Ki67 positive 
cells using Ki67 antibody (Santa Cruz) at a dilution of 1:100.
Sca-1+ Progenitor Cells From Adult Murine Hearts
Isolation and culture of Sca-1+ cells
Wild type Friend leukemia virus strain B (FVB) mice of either sex 
at an age of six to eight weeks were used for the experiments. All 
animal experiments were performed in accordance with the Guide 
for the Care and Use of Laboratory Animals published by the U.S. 
NIH (NIH Publication no. 85-23, revised 1985). Experimental 
protocols were approved by the local animal care committee of 
Mecklenburg-Vorpommern (Landesamt für Landwirtschaft, 
Lebensmittelsicherheit und Fischerei Mecklenburg-Vorpommern). 
Sca-1+ cells were isolated from healthy mouse hearts using magnetic 
cell sorting according to an adapted version of previously published 
protocols (Samal et  al., 2012). Mice were anesthetized with 
isoflurane and sacrificed via cervical dislocation. Extracted hearts 
were minced and incubated with DNase (0.01%) and Liberase (28 
U/ml) (Roche Applied Science) in buffer containing 1 x Hank’s 
buffered salt solution (Invitrogen), 10 mM HEPES, 30 mM taurine, 
4 mM NaHCO3, at pH 7.2 for 15 min at 37°C. During incubation 
the homogenates were mixed thoroughly every 5 min and fresh 
buffer was added. Then the mixture was filtered through a 70 μm 
strainer to remove cardiomyocytes and undigested tissues. Lineage 
positive cells representing mature hematopoietic cells like T cells 
(CD4+, CD8+); B cells (B220+), macrophages (Mac-1+), granulocytes 
(Gr-1+), and erythrocytes (Ter-119+) were depleted using the lineage 
cell depletion kit from Miltenyi Biotec via magnetic cell sorting 
(AutoMACSpro), according to the manufacturer’s instructions. 
Remaining lineage negative cells were re-suspended in 90 μl MACS 
running buffer (phosphate buffered saline, pH 7.2, 2 mM EDTA, 
0.5% bovine serum albumin) per 107 cells and incubated with 
10 μl of Biotin-conjugated anti-Sca-1 antibody (BD Biosciences 
Pharmingen) as provided by the supplier for 10 min at 4°C. 
Afterwards 2 ml of running buffer was added to the cell suspension 
followed by centrifugation at 300 × g (4°C, 10 min). Cell pellets 
were resuspended in 80 μl running buffer followed by incubation 
with 20 μl of anti-biotin micro beads (Miltenyi Biotec) per 107 cells 
for 15 min at 4°C. Cells were sorted again using magnetic cell 
sorting. The magnetically labeled fraction was considered as Sca-
1+ cells and the remaining heterogeneous cell population as Sca-
1-. Sca-1+ cells were seeded at a density of 32.000 cells per cm2 in 
25 cm2 culture flasks and cultivated using Dulbecco’s Modified 
Medium and Nutrient Mixture F-12 (DMEM/F12 3:1, Invitrogen) 
supplemented with 20% FBS (Invitrogen) at 37°C in humid air 
with 5% CO2 for 2 days to ensure sedimentation of fibroblast-like 
cells. Suspension cells were used for further experiments.
Live cell proliferation assay
For proliferation experiments, Xcelligence technology and 
the RTCA DP Analyzer (ACEA, Biosciences) were used. 
This system continuously monitors cell proliferation by 
microelectronic cellular impedance detection (= cell index). 
To determine the proliferation rate an E-Plate (16 wells) 
containing micro fabricated gold electrode arrays was used. The 
E-plates were coated with 0.1% gelatin (Cell Biologics) for 24 h 
at 37°C. Sca-1+ cells (1x104 cells) were seeded using 200 µl of 
media containing WS®1442 and fractions/eluates. 1) WS®1442 
100 µg/ml, 50 µg/ml, and 25 µg/ml; 2) Ultraretentate 25 µg/ml, 
10 µg/ml, and 5 µg/ml; and 3) MeOH eluate 25 µg/ml, 10 µg/ml, 
and 5 µg/ml. Medium with DMSO (final concentration 0.1%) 
was used as control. The proliferation rate was monitored up to 
72 h using the RTCA DP Analyzer software. Each proliferation 
experiment was repeated at least four times using cells from a 
separate isolation employing two technical replicates.
Quantification of the Sca-1+ fraction by FACS 
The percentage of Sca-1 expressing cells after 72 h treatment with 
media supplemented with different concentrations of WS®1442, 
Ultraretentate or the MeOH extract was determined using flow 
cytometry (BD LSR II Flow Cytometer, BD Bioscience). Cells were 
stained with an antibody against Sca-1 (anti-Sca-1 PE-Vio770, 
Miltenyi Biotec) for 10 min at 4°C, washed twice with PBS, and 
analyzed regarding the presence of surface marker Sca-1.
Tube formation assay for angiogenesis
Tube forming capacity of Sca-1+ cells in response to media 
supplemented with WS®1442 or the methanol fraction was 
assessed using a fibrin gel in vitro angiogenesis assay kit (Merck). 
A mixture of fibrinogen and thrombin was pipetted into each 
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well of a 24-well plate and left to polymerize for 60 min at 37°C. 
Sca-1+ cells were seeded with 1 ml of test media into fibrin-coated 
wells at a density of 104 cells per well. Medium with DMSO was 
used as control. Cells were allowed to grow for 72 h before digital 
images of 3–4 random microscopic fields were acquired using a 
Keyence microscope. Tubule length was calculated using ImageJ 
software (U. S. National Institutes of Health).
Western Blots
Cells were washed with PBS and lysed with ice cold Cell Lysis 
Buffer (Cell Signaling) supplemented with protease (Roche) 
and phosphatase inhibitor cocktails (Sigma Aldrich). The 
bicinchoninic acid method was used for protein quantification 
using Pierce BCA Protein Assay Kit (Thermo Scientific) according 
to the manufacturer’s protocol. Lysates were applied to SDS-
PAGE (12% SDS-tris glycine) and transferred to 45  µm PVDF 
membranes (Merck Millipore), which were blocked and stained 
using Odyssey® Blocking Buffer (Li-Cor). Primary antibodies 
were incubated overnight at 4°C using a GFP antibody (AnaSpec) 
and anti-myosin heavy chain (eBioscience) at a dilution of 1:100. 
Anti-α tubulin (Sigma Aldrich) and anti-Gapdh (Cell Signaling) 
were used as loading controls (1:5,000). Following washes with 
TBST buffer, secondary antibodies were incubated for 2 h at RT 
using goat anti-mouse IRDye680 (Li-Cor Bioscience) and goat 
anti-rabbit IRDye800 (Li-Cor Bioscience) at 1:10,000 dilutions. 
Imaging was done with an Odyssey CLx Imaging System (Li-Cor).
rT-PCr
RNA was isolated from differentiating mESCs (32 wells of a 384-well-
plate pooled) at indicated times using TRIsure™ reagent (Bioline) and 
phenol/chloroform extraction method according to the manufacturer’s 
protocol. cDNA samples, synthesized from total RNA with qScript 
cDNA Synthesis Kit (Quanta Bioscience), were run on a LightCycler 
480 (Roche) using Takyon™ SYBR MasterMix (Eurogentec). Relative 
expression levels and significance were determined using the ΔΔCt 
method. The primer sequences are as follows: Acta2 (smooth muscle 
cells): forward primer ACTACTGCCGAGCGTGAG, reverse primer 
TGCTGTTATAGGTGGTTTCGTG; Pecam (endothelial cells): 
forward primer GAAGCCAACAGCCATTACGG, reverse primer 
GGAGCCTTCCGTTCTTAGGG; Mesp1 (cardiac mesoderm): 
forward primer CCATCGTTCCTGTACGCAGA, reverse primer 
CTAGAAGAGCCAGCATGTCG; Mef2c (cardiac progenitors): 
forward primer AGATCCCGATGCAGACGATT, reverse primer 
AGACCGCCTGTGTTACCTG; Tnnt2 (cardiomyocytes): forward 
primer CAGAGGAGGCCAACGTAGAAG, reverse primer 
TCGATCAGAGTCTGTAGCTCATT.
Transcriptome Analyses
Cardiac differentiation assays in mESCs were performed as 
described above and cells treated on day 4 with vehicle control 
(DMSO, n = 2), WS®1442 (0.25 mg/ml, n = 3), or MeOH eluate (0.1 
mg/ml, n = 3) for either 6 or 24 h before cells were collected for RNA 
extraction (= total of 16 samples). RNA extraction was performed by 
OakLabs. Briefly, quality control of RNA samples was accomplished 
with the 2100 Bioanalyzer (Agilent Technologies) using the RNA 
6000 Pico Kit. For quantity control, a photometrical measurement 
with the Nanodrop 2000 spectrophotometer (Thermo Scientific) 
was performed. For labeling, the Low Input QuickAmp Labeling 
Kit (Agilent Technologies) was used to generate fluorescent cRNA. 
For 1st strand synthesis, either oligo-dT primer or a random primer/
oligo-dT primer mixture was used. After 2nd synthesis, an in vitro 
transcription for synthesis of cRNA labeled with cyanine 3-CTP 
was performed. For hybridization, the Agilent Gene Expression 
Hybridization Kit (Agilent Technologies) was used according to the 
manufacturer’s instructions. Fluorescence signals on microarrays 
were detected by the SureScan Microarray Scanner (Agilent 
Technologies). Data of all samples were quantile normalized using 
the ranked mean quantiles according to Bolstad et al. (2003). For 
functional annotation Qiagen IPA software was used. Commonly 
regulated genes upon WS1442- and MeOH eluate-treatment were 
further evaluated and considered to be relevant when log2 (fold 
change) > +1 (up-regulation) or < -1 (down-regulation), compared 
to the DMSO control (p value < 0.05).
Statistical Analyses
All data are shown as mean ± SEM for at least three independent 
biological replicates. Statistical analyses were performed using 
one-way ANOVA or Student’s t-test for pairwise comparisons. 
For transcriptome analyses (see Transcriptome Analyses), 
OakLabs performed normalization and statistics according to 
Bolstad et al. (2003).
rESUlTS
Crataegus Extract WS®1442 Promotes 
Cardiomyogenesis From Pluripotent Stem 
Cells
Initial experiments were designed to detect cardiogenic effects 
of the finished dosage form, i.e. the proprietary medicinal 
product including its pharmaceutical adjuvants. For this, 
Crataegutt® liquid was prepared under aseptic conditions for 
testing on cardiac differentiation from human (hESCs) and 
murine pluripotent embryonic stem cells (mESCs). A directed 
differentiation protocol was used on human embryonic stem 
cells (H9-hESCs, MYH6-mCherry reporter) (Willems et al., 
2011). After mesoderm was formed, cells were replated on day 
4 and treated with Crataegutt® liquid at different concentrations 
during five days (Figure 1A). Cardiogenesis was stimulated in 
a concentration-dependent fashion. Moreover, a spontaneous 
differentiation protocol for murine embryonic stem cells (CGR8-
mESCs, Myh6-eGFP reporter) was adapted and differentiating 
mESCs were exposed to Crataegutt® liquid from day 3 to day 
7 (Figure 1B) (Willems et al., 2012). Again, cardiomyocyte 
differentiation was effectively enhanced by Crataegutt® with 
no signs of cell toxicity, but with the formation of functionally 
beating cardiomyocyte clusters that could be typically detected 
between day 10 to 11 of differentiation. Contributions of the 
adjuvants in the product (i.e., glycerol, propylene glycol, und 
sorbitol) to the observed activity could be excluded since these 
components were inactive in mESC cardiac differentiation (data 
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not shown). Therefore, for all following studies WS®1442 extract 
was used, which revealed a similar dose-dependent activity as 
Crataegutt® liquid. Cardiomyogenic activity was restricted to 
post-mesoderm phases of differentiation, with strongest effects 
during day 4–6 (Figure 1C).
To exclude potential unspecific fluorescence artefacts caused 
by either WS®1442 and/or Myh6-eGFP reporter cells, several 
validation experiments were performed (Figure 1D–I). Image-
based analysis (in the GFP channel) was done with wild-type (WT) 
versus reporter mESCs both treated with WS®1442 between days 
4–6 of differentiation (Figure 1D). Very low GFP fluorescence was 
captured in WT mESCs on day 11 indicating a detectable but low 
background fluorescence with the highest signal being attributed 
to Myh6-eGFP expression. Reporter signal correlation to 
endogenous expression of α-MHC was evaluated via side-by-side 
quantification of cardiomyocyte clusters. Simultaneous analysis of 
Myh6-eGFP (GFP-channel) and α-MHC (after immunostaining, 
Cy5 channel) revealed a high degree of correlation (Figure 1E). 
Confocal microscopy of formed Myh6-GFP+ and α-MHC-stained 
cardiomyocyte clusters are depicted in Figure 1G. Video S1 
illustrates beating cardiomyocyte clusters formed upon treatment 
with WS®1442. The correlation of GFP- and MHC-expression was 
further confirmed by Western blot analysis (Figure 1I). Absolute 
quantification of cardiogenesis was accomplished by flow 
cytometry on day 11 in WS®1442-treated reporter mESCs under 
spontaneous differentiation conditions (Figure 1F). WS®1442 
treatment robustly induced cardiomyocyte formation up to a 
level of 4–5% (i.e., 5–10-fold over DMSO control). Moreover, WT 
CGR8-mESCs were differentiated under the same conditions as 
described for the CGR8-Myh6-eGFP reporter cells and exposed 
to WS®1442 between days 4–6. The cardiogenic effect could be 
visualized using a distinct, cardiomyocyte-specific marker (i.e., 
cTnT) which revealed similar phenotypes in WT and reporter 
cells (Figure 1H).
Bioassay-guided Fractionation and 
Phytochemical Analysis reveal Distinct 
OPC Profiles and Suggest High-Molecular 
Weight Components as Bioactive Principle
In order to gain insights into specific extract components that 
are responsible for the stimulation of cardiac differentiation, 
FigUrE 1 | Crataegus extract WS®1442 stimulates cardiogenesis from human and murine embryonic stem cells. (A, B) Identification of WS®1442-induced 
cardiogenesis in (A) human and (B) murine embryonic stem cells after 5-day treatment with different concentrations of Crataegutt®. (C) Validation of dose- and time-
dependent cardiogenic activity of WS®1442 in mESCs at different phases of differentiation. (D) Image-based quantification of unspecific fluorescence using mESCs 
from WT and reporter (Myh6-GFP) cell lines cultivated under the same conditions. (E) Correlation of αMHC- and αMHC-GFP expression of WS®1442-treated mESCs 
using anti-MHC-antibody. (F) Flow cytometry-based quantification of GFP+ and MHC+ cells after 2-day treatment of mESCs with 0.25 mg/ml WS®1442 or DMSO. 
(g, H) Immunostaining of day 11 mESCs from WT and reporter cell line to assess the expression of cardiomyocyte markers after 2-day treatment with 0.25 mg/ml 
WS®1442 from day 4 to day 6. (i) Validation of dose-dependent αMHC- and αMHC-GFP expression in WS®1442-treated mESCs (Western blot). WT = wild type.
Frontiers in Pharmacology | www.frontiersin.org November 2019 | Volume 10 | Article 1357
WS®1442 Stimulates Cardiovascular Stem CellsHalver et al.
7
bioassay-guided fractionation of the extract WS®1442 was 
performed. Since WS®1442 has already been comprehensively 
characterized, the herein presented, initial approach was to use 
literature-described fractionation protocols to narrow down 
potential bioactive compounds or compound classes. Thus, 
WS®1442 was processed according to Chatterjee et al. (1997), 
yielding an ethyl acetate, ultrafiltrate and an ultraretentate 
fraction. All fractions were evaluated for potential cardiogenesis 
in differentiating mESCs (Figure 2A) (Chatterjee et al., 1997). 
Only the ultraretentate fraction exhibited a pronounced, 
concentration-dependent cardiogenic effect.
Since this fraction has been reported to contain mainly high-
molecular weight components (Chatterjee et al., 1997), including 
oligomeric procyanidines (OPCs) (Figure 2A, 53.5%), a further 
fractionation protocol was employed according to Vennat 
et al. (1992) that enabled discrimination of OPCs with distinct 
degrees of polymerization (DPs) by preparative chromatography 
on a Sephadex® LH20 stationary phase (Vennat et al., 1992). 
This protocol by Vennat et al. was originally described for the 
characterization of OPCs from Hamamelis virginiana L. and 
adapted to prepare comparable fractions from WS®1442 (Figure 
2B). Fractionation was performed by a step gradient with water, 
ethanol (EtOH eluate), methanol (MeOH eluate), and acetone 
(acetone eluate). Phytochemical analysis of these eluates revealed 
a comparable composition as originally described for Hamamelis 
extract, with high concentrations of flavones in the EtOH eluate 
(25.9%) as well as high levels of OPCs in the MeOH (56.3%) 
and acetone (60.1%) eluates (see Figure 2B). The water eluate 
consisted of low molecular weight components and turned 
out to be inactive (Figure 2B). Also the DP1 OPC-enriched 
EtOH eluate, which contained mainly monomeric flavan-3-
ols, dimeric and trimeric proanthocyanidins did not stimulate 
cardiac differentiation. However, the MeOH and acetone eluates 
showed strong concentration-dependent cardiogenic effects. 
Video S2 shows beating cardiomyocyte clusters formed upon 
treatment with MeOH eluate. These results were in agreement 
with cardiogenic activity profiles of the fractions according to the 
protocol by Chatterjee et al. (1997), since high-molecular weight 
components appear to be responsible for the observed effects on 
cardiac differentiation.
In addition, a set of 15 single compounds was tested, which 
have been reported as Crataegus secondary metabolites. They 
were inactive in the cardiogenic assay (Figure 2C). Following the 
hypothesis that OPCs could account for the cardiogenic activity, 
defined OPC clusters were isolated from hawthorn as described 
previously, followed by systematic functional evaluation (Sendker 
et al., 2009; Zumdick et al., 2009). OPCs with an average DP of 
7 or higher exhibited cardiogenic activity, although to a much 
FigUrE 2 | Evaluation of isolated WS®1442 fractions/eluates for cardiogenic activity in mESC differentiation. (A) Murine ES cells were cultured in 384-well format 
for 11 days and treated with different concentrations of fractions according to Chatterjee et al. from day 4 to day 6 (Chatterjee et al., 1997). (B) Concentration-
dependent effect on cardiogenesis of mESCs after 2-day treatment with fractions/eluates using a protocol from Vennat et al. determined by Western blot and 
imaging analysis (Vennat et al., 1992). (C, D) Image-based quantification of cardiogenic activity after 2-day treatment with (C) Crataegus-related ingredients and 
(D) isolated oligomeric procyanidins (OPCs) with defined DP, where DP2 represents dimeric procyanidins, n = 1 equals DP3, n = 2 equals DP4, etc. a % Flavones 
quantified according to Ph. Eur. (Ed. 9), b % OPCs quantified with Folin-Ciocalteu reagent.
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lower extent (ca. 5–10-fold less effective) compared to WS®1442 
extract, ultraretentate, and MeOH fractions, respectively.
Following the preliminary phytochemical analysis and 
functional testing of fractionated WS®1442 (Figure 2A, B), more 
elaborated analytical studies were needed to identify putative 
cardiogenic components. Thus, WS®1442 and its fractions/eluates 
were characterized by LC-MS using RP18 chromatography and 
by LC-FD using a diol stationary phase in HILIC mode. The latter 
method, separates OPCs according to their DP (Sendker et al., 
2009; Zumdick et al., 2009). OPCs up to DP12 were detected in 
WS®1442 along with a polymer peak, which can be assumed to 
contain OPCs constituted of more than 12 flavan-3-ol units (see 
Figure S2).
We found that the distribution of OPCs—based on DP—was 
rather homogenous in WS®1442 and gradually decreased with 
higher DP. In contrast, fractionation according to Vennat et al. 
(Figure 2B) yielded products of distinct OPC distribution (Figure 
3): The water eluate was void of OPC apart of small amounts of 
flavan-3-ol monomers, which were enriched by almost 10-fold 
in the EtOH eluate. The major OPC part of DP2–10 eluted with 
MeOH with a particular strong enrichment of DP2–5. The OPC 
distribution of the acetone eluate resembled that of WS®1442 
apart from smaller overall peak areas, obviously a consequence 
of the earlier elution with methanol.
The OPC distribution of the ultraretentate from the 
fractionation protocol by Chatterjee et al. (1997) showed an 
enrichment of DP4–9, although their absolute concentrations 
were about 50% lower than in WS®1442. Polymer peaks of 
comparable size were observable in all fractions except for the 
water and EtOH eluates.
In addition, LC-MS was used to analyze the composition of 
OPCs, OPC-related constituents, and other ingredients of WS®1442 
and its fractions (Table S1). OPC patterns were observable by 
LC-MS up to DP8, whereas only diffuse increases in the extracted 
ion chromatograms indicated the presence of DP9–12 (Figures 
S3, S4). Cinchonains of DP1–6 were detected in WS®1442 and 
its fractions, with estimated relative amounts of 5–10% of their 
respective OPC for DP3–6 but 30–40% for DP1‒2 (Table S1). 
OPC hexosides (DP1–5) were characterized on the basis of their 
exact masses and fragmentation patterns (Figures S4, S5), with 
FigUrE 3 | LC-FD-based characterization of WS®1442 and isolated fractions thereof. (A) Apparent distribution of oligomeric procyanidines (OPCs) and polymer 
peaks, data show the square root (sqrt) of the peak areas; (B) Enrichment of OPC and polymers relative to WS®1442 extract.
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DP2 hexosides representing the most abundant ones (see Table 
S1). OPC hexosides up to DP2 have previously been described 
in C. laevigata and C. monogyna (Karar and Kuhnert, 2015). Low 
molecular weight compounds, e.g., flavonoids as monomers, 
caffeic acid derivatives, and triterpenes, were also detected using 
LC-MS and characterized by the product ion spectra of the 
deprotonated molecules (see Tables S2, 3).
WS®1442 and its Active Fractions 
Stimulate Differentiation but not 
Proliferation of Cardiovascular Progenitor 
Cells In Vitro
With analytically more defined, potently bioactive fractions in 
hand (i.e., ultraretentate and MeOH), WS®1442 was further 
characterized with regards to mesodermal and cardiovascular 
cell-fates in mESCs when applied between D4–6 of differentiation. 
Figure 4A shows the qPCR analysis of endothelial (Pecam1) and 
smooth muscle cell (Acta2) markers on day 11 of differentiation. 
The data revealed that the formation of vascular cells is significantly 
but very low stimulated by WS®1442 and MeOH eluate, whereas 
the cardiomyocyte marker Tnnt2 is highly upregulated upon 
treatment (30- and 45-fold, respectively). Next, we asked 
whether certain mesodermal or cardiovascular progenitor 
cells are affected by WS®1442 or MeOH eluate treatment and 
determined the expression profiles of the mesodermal marker 
Mesp1, the cardiac progenitor cell marker Mef2c, and the 
cardiomyocyte marker Tnnt2 by qPCR during the entire course 
of mESC differentiation (Figure 4B). Treatment with WS®1442 
or MeOH did not alter Mesp1 levels compared to DMSO while 
Mef2c was significantly upregulated. Tnnt2 expression was also 
upregulated with a slight delay compared to Mef2c with highest 
levels on D11. Cardiomyocyte subtype-specific markers were 
analyzed on D11 of differentiation (Figure 4C). MeOH eluate-
treated mESCs showed higher levels of the atrial marker Mlc2a 
compared to the ventricular marker Mlc2v. Next, we addressed 
whether these cardiovascular progenitor cells were indeed pushed 
towards cardiac differentiation or if WS®1442, MeOH eluate and 
ultraretentate promoted their proliferation. Figure 4D summarizes 
experiments in which WS®1442-treated mESCs were analyzed in 
FigUrE 4 | Characterization of WS®1442 and its active fractions on mesodermal differentiation cell-fates and cell proliferation during mESC differentiation. 
(A, B) Quantitative PCR-based measurement of (A) mesodermal and (B) cardiac differentiation markers of mESCs treated with DMSO, 0.25 mg/ml WS®1442 
or 0.1 mg/ml MeOH eluate from day 4 to day 6. (C) Effect on cardiomyocyte subtype specification after 2-day treatment with WS®1442 and MeOH eluate (p ≤ 
0.05 = *, p ≤ 0.01 = **, p ≤ 0.001 = ***, p ≤ 0.0001 = ****). (D) Image-based quantification of DAPI and Ki67 positive cells after 0-, 12-, 24-, and 36-h treatment 
of mESCs with 0.25 mg/ml WS®1442 or DMSO at day 4. (E) Cell proliferation and viability assay measuring metabolic activity on day 5 and day 6 mESCs after 
1- and 2-day treatment with different doses of WS®1442 and fractions/eluates.
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a time-dependent fashion by automated imaging for cell number 
(nuclei, DAPI channel) and the cell cycle/proliferation marker 
Ki67 (GFP channel). Neither cell number nor cell cycle activity 
were significantly changed compared to DMSO treatment. Both 
DMSO- and WS®1442-treatment led to a decrease in Ki67-related 
proliferative activity in several independent experiments. This 
effect is most likely reflecting the continuous consumption of 
media supplements/serum with cell growth and differentiation 
over two days. However, we still asked whether cell viability 
(via quantification of reductive metabolism) is affected upon 
treatment. Figure 4E shows that WS®1442 and all its cardiogenic 
fractions (ultraretentate, MeOH, and acetone) do not disturb 
cell viability/metabolism after 24 h exposure. Only an extended 
treatment with WS®1442 and MeOH eluate had a negative effect 
on cell viability, a phenomenon that could be explained by stress-
induced molecular mechanisms which were also suggested from 
transcriptome analyses (see WS®1442 Stimulates Angiogenesis but 
Not Proliferation of Isolated Sca-1+ Progenitor Cells From Murine 
Hearts Ex Vivo, Figure 5).
genome-Wide Transcriptome Analysis 
reveals Multiple Molecular Targets and 
Pathways
Changes in global gene expression patterns were addressed by 
transcriptome analysis of differentiating mESCs after treatment 
FigUrE 5 | Transcriptome profiling of differentiating mESCs upon WS®1442 and MeOH eluate treatment. (A) Murine ES cells were cultured in a 384-format, treated 
with DMSO, 0.25 mg/ml WS®1442 or 0.1 mg/ml MeOH eluate at day 4. Part of the cells were collected after 6 h or 24 h for transcriptome analysis while the rest 
was cultured until day 11 (after 2-day treatment) for validation of cardiomyogenesis. (B–E) Annotation of commonly down- and up-regulated genes after (B, D) 6 h 
and (B, E) 24 h treatment with WS®1442 and MeOH eluate (log2[fold change] > 1 or -1, p-value < 0.05) using Qiagen IPS network analysis for (C–E) determination 
of upstream regulators, gene functions, targets, and location.
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with WS®1442 (0.25 mg/ml) and of its active fraction MeOH 
eluate (0.1 mg/ml) between days 4–6. The experimental setup 
is outlined in Figure 5A: RNA was isolated for transcriptome 
profiling after 6 h and 24 h of treatment. To assure that mESC 
differentiation and the assay worked, controls were evaluated 
by image analysis from the same 384-well plate on day 11. 
These controls showed the typical 2-fold greater cardiogenic 
activity of the MeOH eluate compared to WS®1442. To confine 
the most relevant involved genes and signaling networks for 
later mechanistic interpretation, we focused on overlapping 
transcripts after WS®1442 and MeOH treatment. Only changes 
in gene expression with fold changes ≥2 and p-values of <0.05 
were considered for data interpretation (see Volcano plots in 
Figures 5D, E).
The overall effect on gene expression was more moderate for 
WS®1442 compared to MeOH eluate. The data showed almost 
2-fold more commonly regulated genes after 24 h compared to 
6 h (18% versus 30%) after WS®1442- and MeOH treatment 
(Figure 5B). Gene ontology analysis and function annotation 
was performed using the Ingenuity Pathway Analysis (IPA) 
software algorithms and showed a prominent effect of WS®1442 
and MeOH treatment on genes associated with cardiovascular 
development and function (score = 82, 37 genes) as well as 
cellular development, growth, and proliferation (score = 45, 24 
genes). Mainly enzymes, kinases, and transcription factors were 
regulated. No specific subcellular localization of the molecular 
targets involved could be extrapolated from the transcriptome 
data since extracellular, plasma membrane, cytosolic, and nucleic 
targets appeared to be almost equally regulated.
IPA-based algorithms which allowed for a global analysis of 
the signaling networks and putative upstream regulators revealed 
that after 6 h particularly tumor suppressor p53 (p53) and brain-
derived neurotrophic factor (BDNF) seem to be mechanistically 
involved. Figure 5C depicts these predicted upstream regulators 
along with their respective associated genes. The p53 (z-score 
+2.20) and BDNF (z-score +1.95) networks were predicted to be 
activated upon WS®1442 and MeOH eluate treatment. Several 
individual candidates of the commonly regulated genes from 
WS®1442 and MeOH eluate treatments are shown in Volcano 
plots (Figures 5D, E; a complete list is available in Figure S6), 
including downregulated effectors from the TGFβ superfamily 
of ligands (i.e., Lefty1, Lzts1, Adamts9) and members of the 
Fox transcription factors (e.g., Foxc2). While the transcriptome 
profiles at 6 h post-treatment provided insights into immediate 
cellular responses, global gene expression levels after 24 h 
should give information regarding the most dominantly 
affected factors and pathways that contribute to the cardiogenic 
phenotypes (Figure 5E). IPA analysis predicted several upstream 
regulators: In line with activated p53 after 6 h, many stress- and 
inflammation-associated genes were affected explaining the 
upregulation of a “lipopolysaccharide (LPS)” network of genes 
(z-score +2.01). On the other hand, TGFβ-1 (z-score -2.28) 
and FGF-2 (z-score -2.15) signaling networks were negatively 
regulated 24 h post-treatment. The Volcano plot in Figure 5E 
highlights Aldh1a2 which was strongly upregulated (5–7-fold, 
p < 0.0001) both by WS®1442 and MeOH eluate implicating the 
involvement of retinoic acid signaling.
WS®1442 Stimulates Angiogenesis But Not 
Proliferation of isolated Sca-1+ Progenitor 
Cells From Murine Hearts Ex Vivo
In an attempt to validate our findings in physiologically relevant 
progenitor cell populations within the heart, (van Vliet et al., 
2012) Sca-1+ progenitor cells (Sca-PCs) were isolated from 
murine hearts (6–8-weeks-old mice) and treated with WS®1442, 
ultraretentate or MeOH eluate (Figure 6A) (Samal et al., 2012). 
WS®1442 and MeOH eluate facilitated and improved PCs’ 
attachment (Figure 6B, cell index after 2 h) but did not accelerate 
proliferation rates. Ultraretentate exhibited a more modest effect. 
In contrast to WS®1442, Sca-PC proliferation rates were slowed 
down after 24–48 h treatment with ultraretentate and MeOH 
eluate. Flow cytometry analysis of WS®1442- and MeOH eluate-
treated progenitor cells after 72 h revealed no significant changes 
in the expansion of Sca-PC populations (Figure 6C).
We further evaluated the influence of WS®1442 on the tube 
forming ability of Sca-1+ cells for 72 h using an angiogenesis 
assay kit (Figure 6D). Quantitative analysis revealed a 
significant increase in tube length upon administration of 
WS®1442 100 µg/ml (2.2-fold, p < 0.01). Lower concentrations 
of WS®1442 did not cause a relevant change in tube formation 
of Sca-1+ cells compared to medium + DMSO (1.3-fold and 1.1-
fold, respectively). On the other hand, treatment with the MeOH 
eluate kept Sca-1+ cells in a monolayer without marked tube 
formation. This finding indicates a concentration-dependent 
pro-angiogenic property of WS®1442 that can induce capillary-
like tubule formation of Sca-1+ progenitor cells.
DiSCUSSiON
Hawthorn (Crataegus spp.) represents a traditional European 
medicinal plant. Extracts from leaves and flowers exhibit well-
documented activities in cardiovascular medicine (Koch and 
Malek, 2011; European Pharmacopoeia, 2017), although the 
quantified hawthorn extract WS®1442 did not improve mortality 
in patients with congestive heart failure (SPICE study, 2008) 
(Holubarsch et al., 2008). Based on the long-standing tradition 
and the documented safety, the EMA classified preparations from 
Crataegus spp. leaves and flowers as “traditional herbal medicinal 
product” for “nervous cardiac complaints, mild mental stress and 
to aid sleep” in 2016 European Medicines Agency, 2016. Several 
studies suggest a positive effect of WS®1442 on heart muscle 
physiology (Koch and Malek, 2011; European Pharmacopoeia, 
2017), including anti-hypertrophic activity as well as reduced scar 
sizes in a rat model of ischemic reperfusion (Veveris et al., 2004; 
Koch and Spörl-Aich, 2006). Hence, the aim of the present study 
was to explore principle mechanisms relevant for a regenerative 
potential of WS®1442 in patients suffering from heart failure 
after myocardial infarction.
Spontaneous and directed differentiation assays using 
pluripotent stem cells have been used as surrogate systems 
to probe cardiac differentiation and regeneration and dissect 
underlying mechanisms (Schade and Plowright, 2015; Spiering 
et al., 2015). In our previous work, we have harnessed such systems 
to identify small molecule stimulators of cardiomyogenesis to 
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generate therapeutic modalities with regenerative potential for 
the infarcted heart (Willems et al., 2011; Lanier et al., 2012; 
Schade et al., 2012; Willems et al., 2012). Here, we showed that 
Crataegutt® liquid, a finished dosage form of the standardized 
hawthorn extract WS®1442, efficiently stimulated cardiac 
differentiation both from human and murine ESCs in a 
concentration-dependent fashion (Figures 1A, B). This activity 
was further confirmed using WS®1442 dry extract with the most 
significant change between days 4–6 (Figure 1C), where typically 
cardiovascular progenitors have already been formed in this 
system (Willems et al., 2012; Cai et al., 2013). WS®1442-based 
stimulation of cardiac differentiation was in the same range 
(i.e., 30–50-fold over control) as that of optimized, single small 
molecules such as the TGFβ receptor type II degraders (Willems 
et al., 2012; Schade et al., 2012), leading to cardiomyocyte yields 
from mESCs in the 4–5% range (i.e., 5–10-fold over control). 
Unspecific fluorescence artefacts from this complex extract in 
the phenotypic, image-based readouts were ruled out in a series 
of experiments (Figure 1D–I).
To obtain first insights into specific compound classes 
responsible for the observed stimulation of cardiac 
differentiation, “bioassay-guided fractionations” were performed. 
The most abundant pharmacologically active substances of 
the leaves and flowers of hawthorn species are flavonoids 
(ranging between 1.5–2.5%) and catechin/epicatechin-derived 
oligomeric procyanidines (OPCs, up to 3.0%). Additional 
components belong to the classes of cinnamic acids, triterpenic 
acids (up to 0.6%), amines/catecholamines, and polymeric 
carbohydrates. (Hensel, 1998; Petereit and Nahrstedt, 2005) 
Quantified Crataegus extracts are well-defined in the European 
Pharmacopoeia (European Medicines Agency, 2016). The water/
EtOH (45%) extract WS®1442 contains about 6.0% flavonoids 
and is standardized to 17.3‒20.1% OPC with a drug/extract ratio 
of 4‒6.6:1 (European Medicines Agency, 2016).
WS®1442 was fractionated according to a protocol described 
by Chatterjee et al. (1997) which partitions the extract between 
ethyl acetate and water, with the latter being subjected to 
ultrafiltration (Figure 2A) (Chatterjee et al., 1997). The resulting 
ethyl acetate, ultrafiltrate, and ultraretentate fractions were tested 
for cardiomyogenesis in mESCs. The ethyl acetate fraction has 
been reported to be enriched in low-molecular weight flavonoids 
(9.7%) and contains OPCs (15.1%), but was inactive. Similarly, 
the ultrafiltrate was inactive and contained flavonoids as well as 
possibly other water-soluble, small molecule components. Only 
FigUrE 6 | Evaluation of WS®1442 and its active fractions/eluates on proliferation and differentiation (angiogenesis) of primary murine Sca-1+ progenitor cells 
(Sca-PCs). (A) Isolation and culture of Sca-1+ cells for three distinct experimental setups; (B) Monitoring of Sca-PC attachment and proliferation by cell impedance 
measurements on 16-well plates, expressed as slope of the linear regression model with cell number as outcome and time as continuous independent variable 
(cell index, XCelligence RTCA DP Analyzer), Mean ± SEM, p ≤ 0.05 = *, p ≤ 0.01 = **, p ≤ 0.001 = *** vs. media plus DMSO (= 100%); (C) Quantification of Sca-1 
expressing cells by flow cytometry (BD LSR II Flow Cytometer); (D) Tube formation assay using a fibrin gel in vitro angiogenesis assay kit, including image-based 
quantification of tube length (Mean ± SEM, p ≤ 0.01 = ** vs. media plus DMSO).
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the OPC-rich (53.5%) ultraretentate fraction dose-dependently 
stimulated cardiogenesis up to 80-fold over control (Figure 
2A). This indicated that OPCs, or rather high-molecular weight 
components, were responsible for bioactivity. Hence, another 
fractionation procedure was employed that has been reported 
to separate OPCs dependent of their DP. Step-wise elution 
of WS®1442 on a Sephadex LH20 column resulted in water, 
EtOH, MeOH, and acetone eluate fractions (Figure 2B). Their 
composition in flavones and OPCs was in good agreement with 
those reported for Hamamelis (Vennat et al., 1992). Both OPC-
rich fractions (i.e., MeOH and acetone eluates) were active in 
the mESC differentiation assay and stimulated cardiogenesis in a 
concentration-dependent fashion up to 70–80-fold (Figure 2B).
Our observation that fractions containing low-molecular 
weight components were inactive was further substantiated 
by screening 15 single substances from Crataegus. None of the 
tested flavone aglykons, flavone glucosides, catechin/epicatechin, 
dimeric and trimeric procyanidines, quinic and triterpenic acids 
stimulated cardiomyogenesis (Figure 2C). In an attempt to 
specifically address OPCs with defined DPs, single OPCs from 
DP2–10 were tested (Figure 2D) (Zumdick et al., 2009). None 
of the tested OPCs could achieve the same biological activity as 
the OPC-enriched ultraretentate, MeOH-, or acetone eluates. 
Only OPCs with a DP >7 showed low cardiogenic activity with 
moderate dose-dependency (see OPC DP10, Figure 2D).
One can speculate that the stability of such single OPCs might 
be compromised, and biological activities potentially require a 
mix of different OPCs. Therefore, all eluates from size exclusion 
chromatography as well as the OPC-enriched ultraretentate 
were comprehensively analyzed by LC-FD and LC-MS. Here, 
we disclose for the first time semi-quantitative OPC distribution 
profiles—along with their qualitative compositions—for 
WS®1442 and its fractions/eluates (Figure 3). OPCs up to DP12 
could be detected using a diol stationary phase in HILIC mode 
(LC-FD). OPC quantities in WS®1442 gradually decreased 
with increasing DP (Figure 3A). The ultraretentate showed a 
similar OPC distribution profile as WS®1442 but lower absolute 
concentrations. OPC DP4–9 as well as the polymers’ peak were 
slightly enriched relative to WS®1442 (Figure 3B). The EtOH 
eluate has been reported to mainly constitute of monomeric 
flavan-3-ols and dimeric/trimeric OPCs (Vennat et al., 1992), 
which was in very good agreement with our OPC distribution 
(Figure 3). However, according to Vennat et al. (1992), the 
MeOH eluate was supposed to mainly contain DP4 OPCs and the 
acetone eluate OPCs with DP > 4 (Vennat et al., 1992). This could 
not be confirmed by our analyses as the MeOH eluate contained 
OPCs from DP2–10, with a clear enrichment of DP2–5 OPCs. 
The acetone eluate exhibited a similar OPC profile as WS®1442, 
but total OPC quantities were much smaller.
Together, these findings suggested that the cardiogenic 
activity of WS®1442 is not mediated by single small molecular 
compounds but is most likely attributable to larger molecules. 
When comparing the OPC distribution profiles of WS®1442 with 
those of all active fractions/eluates, DP3–5 OPCs are particularly 
enriched, and thus, represent a potentially pro-cardiogenic 
OPC cluster. This is interesting because an OPC-mediated 
differentiation-promoting effect has already been reported in 
the context of wound healing, although only for procyanidin B2 
and not for DP3–4 OPCs (Kisseih et al., 2015). Another report 
described a potential regenerative activity of DP2–4 OPCs 
on dental mineralization via stimulation of dental pulp cells 
(Kulakowski et al., 2017). It should be noted that WS®1442 and 
all cardiogenic fractions/eluates contain significant amounts 
of, yet undefined, polymers. These polymeric components are 
enriched up to 1-fold in the bioactive ultraretentate and eluates. 
Thus, it is conceivable that at least part of the differentiation-
promoting activity is conferred by highly polar, low-soluble 
polymers, such as polymeric carbohydrates. Future studies 
should specifically focus on OPC clusters DP3–6 and determine 
their constitutions. We already found unprecedented OPC 
C-hexosides in the present study (see Supporting Information). 
Additional preparative chromatography will be required in 
order to investigate the polymeric carbohydrate components. 
In general, it is not inconceivable that other herbal extracts 
with similar and ubiquitously present ingredients such as OPC 
clusters of DP3–6 exert comparable stimulating activities on 
cell differentiation.
The well-characterized ultraretentate and MeOH eluate with 
“enriched cardiogenic activities” as well as WS®1442 were further 
investigated with regards to mesodermal and cardiovascular cell-
fates in differentiating mESCs. qPCR data for the vascular markers 
Pecam1 (endothelium) and Acta2 (smooth muscle) indicated 
that the formation of vascular cells is neither stimulated by 
WS®1442 nor by MeOH eluate, whereas Tnnt2 (cardiomyocytes) 
was highly upregulated (30- and 45-fold) (Figure 4A). In 
addition, quantification of the atrial (Mlc2a) and ventricular 
(Mlc2v) cardiomyocyte markers pointed at a possible effect on 
cardiomyocyte subtype-specification (Figure 4C). In particular, 
MeOH eluate appeared to induce higher levels of the atrial marker 
Mlc2a. Directing subtype-specification during differentiation is 
of general interest in stem cell research as it improves the quality 
of available safety pharmacology models and screening platforms 
(Devalla et al., 2015; Cyganek et al., 2018). To date, several molecules 
and pathways have been described that favor distinct cardiac cell-
fates. One prime factor for subtype specification in vivo is retinoic 
acid (RA) (Duester, 2008), which indeed seemed to be regulated by 
WS®1442 and MeOH eluate as transcriptome data suggested (see 
Figure 5 and below).
We addressed if mesodermal or cardiovascular progenitor 
cells are affected by WS®1442 and MeOH eluate. qPCR-based 
expression analysis of Mesp1 (mesoderm) and Mef2c (cardiac 
progenitor cells, CPCs) during the 11-day mESC differentiation 
assay revealed that mesodermal cells are not expanded but that 
transition to Mef2c+ progenitor cells is stimulated (Figure 4B). 
With a slight delay compared to Mef2c, also Tnnt2 expression 
was upregulated with highest levels on day 11 of differentiation. 
To address whether progenitor cells were indeed pushed towards 
cardiac cell-fates instead of being expanded by proliferation, 
WS®1442-, MeOH eluate-, and ultraretentate-treated (D4–6) 
mESC cultures were analyzed by automated imaging for cell 
number and the cell cycle/proliferation marker Ki67 (Figure 
4D). However, no significant changes in cell number or cell 
cycle activity were detected. Together, these data underlined that 
WS®1442 and its bioactive fractions stimulated cardiovascular 
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progenitor cells towards cardiac differentiation after mesodermal 
cells have been formed, whereas pro-proliferative effects did not 
contribute to cardiomyogenesis.
To gain first mechanistic insights, gene expression profiles 
were obtained from differentiating mESCs after 6 h and 24 h 
treatments with WS®1442 and MeOH eluate (Figure 5A). 
Genes regulated by both treatments were considered for gene 
ontology (signaling network) analyses which revealed a greater 
overlap after 24 h (30%) as opposed to 6 h (18%). Particularly, 
genes associated with cardiovascular development and function 
as well as cellular development, growth and proliferation were 
regulated (Figure 5C). This is expected, in line with the observed 
phenotypes (Figure 1) and characterizations of mesodermal 
and cardiovascular cell differentiation fates (Figure 2). The 
fact that mainly enzymes, kinases, and transcription factors 
were altered (Figure 5C) indicated strong effects on signaling 
transduction pathways.
From this transcriptome data, IPA-algorithms predicted the 
mechanistic involvement of distinct upstream effectors like tumor 
suppressor p53 which was activated after 6 h (z-score +2.20, 
Figure 5D). It is a key player in many biological processes such 
as apoptosis, genomic stress and stability, cellular aging, as well as 
stem and progenitor cell maintenance (Riley et al., 2008; Levine 
and Oren, 2009; Lin and Lin, 2017). Thus, upregulation of the p53 
network could explain an immediate cellular response to WS®1442/
MeOH eluate-caused stress besides promoting differentiation 
as opposed to maintaining a given developmental state (“stable 
expansion”). Stress- and inflammation-associated genes were 
also affected after 24 h (Figure 5E) explaining the upregulation 
of a “lipopolysaccharide (LPS)” network of genes (z-score +2.01). 
Therefore, it is conceivable that a significant part of the molecular 
mechanisms in WS®1442’s and MeOH eluate’s stimulation of 
cardiac differentiation is linked to an increased release of pro-
inflammatory cytokines, eicosanoids, nitric oxide (NO), and/or 
reactive oxygen species (ROS) which exert a pro-differentiation 
effect. In general, such mechanisms have been demonstrated 
for ROS and NO in the context of mESC cardiac differentiation 
(Sauer et al., 2000; Bartsch et al., 2011). NO- and ROS-associated 
molecular mechanisms have already been proposed for Crataegus 
extracts in different cellular context (Koch and Chatterjee, 2000; 
Anselm et al., 2009). Stress-associated mechanisms were in 
agreement with data from cell viability assays which revealed 
decreased metabolic activity after 48 h treatment with WS®1442 
and MeOH eluate compared to DMSO control (Figure 4E).
After 6 h of treatment, brain-derived neurotrophic factor 
(BDNF) was also predicted to be activated (z-score +1.95) as an 
upstream regulator. This is interesting because BDNF has been 
shown to exhibit several functions beyond the central nervous 
system. For example, BDNF overexpression is associated with an 
increased capillary density in heart tissue and reported to exert 
protective effects in coronary heart disease (Lorgis et al., 2010; Jiang 
et al., 2011; Kaess et al., 2015; Pius-Sadowska and Machaliński, 
2017). Samal et al. (2015) showed that BDNF is increased in 
Sca-1+ progenitors from the failing heart and contributed to 
the cardiogenic potential of these cells via stimulation of cell 
migration (Samal et al., 2015). Additional potential immediate 
effectors of WS®1442 and MeOH eluate could be linked to the 
TGFβ superfamily of ligands, including nodal (e.g., Lefty1 as a 
negative regulator of nodal) and bone morphogenetic protein 
(BMP) (e.g., Lzts1) which were significantly downregulated. 
These belong to the many well-known cardiopoietic signaling 
pathways that have been characterized for their spatio-temporal 
roles in heart morphogenesis, cardiomyocyte formation and 
specification (Noseda et al., 2011; Burridge et al., 2014; Paige et al., 
2015; Spiering et al., 2015). Consistent with this data, the TGFβ-1 
network was also found to be negatively regulated (z-score -2.28) 
after 24 h of treatment (Figure 5E). The requirement of TGFβ 
inhibition for effective cardiac differentiation has been shown by 
several groups, including our own work on a novel class of small 
molecular TGFβ inhibitors (Willems et al., 2012; Schade et al., 
2012; Langle et al., 2019). Another downregulated signaling 
network after 24 h was FGF-2 (z-score -2.15) which is also well-
recognized as a cardiogenic factor in stem cell differentiation 
and cardiac reprogramming from fibroblasts (Itoh et al., 2016). 
An interesting observation was the strong upregulation of 
Aldh1a2 (5–7-fold, p < 0.0001) by both WS®1442 and MeOH 
eluate. Aldh1a2 encodes for the retinaldehyde dehydrogenase 
2 (Raldh2) which catalyzes the last step in the biosynthesis of 
retinoic acid (RA), i.e. the oxidation of retinaldehyde to RA. The 
pivotal role of RA in heart development and cardiomyogenesis 
is well-known (Moss et al., 1998; Ross et al., 2000). Many groups 
have reported that RA signaling contributes to cardiomyocyte 
specification with RA stimulation promoting an atrial over 
ventricular phenotype in differentiating murine and human ESCs 
(Gassanov et al., 2008; Zhang et al., 2011; Quaranta et al., 2018). 
A potential regulation of RA signaling by Crataegus extract is 
intriguing as the formation of atrial cardiomyocytes appeared 
to be favored over ventricular cells (see Figure 4C). However, 
the timeline of differentiation is not long enough in this setup to 
determine whether true subtype-specification is induced. Long-
term culturing of differentiated ESC-derived cardiomyocytes and 
electrophysiological characterizations would be required.
Based on the transcriptome data, two plausible mechanisms 
for the differentiation-promoting activity of WS®1442 seemed 
to emerge: Early, stress-associated cellular events along with 
the perturbation of discrete developmental pathways, including 
the downregulation of TGFβ/BMP and FGF and the activation 
of BDNF- and RA-linked signaling. Future studies will have to 
dissect the activities of Crataegus extract, fractions/eluates, and 
ideally, further isolated compound classes on these pathways in 
cardiovascular progenitor cell populations.
As cardiovascular progenitors seem to be targeted, we aimed 
at investigating effects of WS®1442 and its bioactive fractions 
on physiologically relevant progenitor cell populations that have 
been characterized to reside within the heart (van Vliet et  al., 
2012; Broughton et al., 2018). The general role and impact of 
cardiac progenitor cells (CPCs) to cardiac regeneration after 
ischemic injury is controversial and has been challenged 
in recent years (Chien et al., 2019), at least regarding their 
contribution to de novo cardiomyocyte generation. Here, 
we used a cell population that has been proposed in the past 
decades as potential CPCs (i.e., Sca-1+ cells). However, it turned 
out to resemble rather endothelial cell phenotypes with minimal 
cardiomyogenic potential in tissue homeostasis and after 
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myocardial infarction (Neidig et al., 2018; Zhang et al., 2018). 
Moreover, genetic lineage tracing of these Sca-1+ cells rather 
suggested a contribution to vasculogenesis in the murine heart 
(Vagnozzi et al., 2018).
This minimal capacity for cardio- and angiogenesis prompted 
us to assess function, differentiation, and proliferation of Sca-1+ 
progenitor cells (Sca-1-PCs) (Samal et al., 2012) from murine 
hearts ex vivo upon treatment with WS®1442, ultratetentate, 
or MeOH (Figure 6A). WS®1442 and MeOH eluate improved 
Sca-1-PC attachment but had no effects on proliferation rates 
(Figure 6B). Ultraretentate treatment exhibited a more modest 
effect. In contrast to WS®1442, Sca-PC proliferation rates were 
slowed down after 24–48 h with ultraretentate and MeOH eluate. 
Flow cytometry analysis of WS®1442- and MeOH eluate-treated 
Sca-PCs after 72-h treatments revealed no significant change 
in the percentage of Sca-1+ cells supporting a stabilizing, pro-
cardiovascular cell-fate activity (Figure 6C). WS®1442 induced 
capillary-like tubule formation of Sca-PCs in a concentration-
dependent fashion (Figure 6D, left) while MeOH eluate-
treatment inhibited this phenotype (Figure 6D, right). This is 
interesting because our transcriptome data on differentiating 
mESCs suggested BDNF as a putative upstream regulator which 
has been described to induce mobilization, angiogenesis, and 
cardiogenic potential of Sca-1+ progenitor cells (Samal et al., 
2015). These opposing effects of WS®1442 and MeOH eluate 
further underline that isolated, primary Sca-1+ cardiovascular 
progenitors represent a distinct cell type compared to cardiac 
progenitors from mESC differentiation. Future studies will 
have to shed light on cardiovascular cell-fates of such Sca-PCs 
after long-term exposure to WS®1442 and MeOH eluate and 
functional consequences thereof. This is particularly appealing 
in view of numerous studies that suggest proangiogenic therapy 
might be promising for patients after acute myocardial infarction 
(Cochain et al., 2013).
In conclusion, the underlying mechanisms for a pro-
differentiation profile of WS®1442 on cardiovascular progenitor 
cells involve rather unspecific stress-associated effects along with 
the perturbation of distinct signaling pathways, such as TGFβ, 
FGF, retinoic acid, and BDNF (Figure 7). It will be critical to 
address to which extent WS®1442 and its bioactive fractions/
eluates contribute to cardiogenic and/or angiogenic potential 
in vivo under physiological conditions as well as after ischemic 
injury, implicating an unprecedented pharmacology of this 
traditional medicinal plant. In this regard, it will be interesting to 
test whether the putative high-molecular weight ingredients (e.g., 
OPC clusters DP3–6 and carbohydrate polymers) show efficacy 
after oral administration. Independent from such bioavailability 
studies, further bioassay-guided fractionations—employing both 
mESC-derived cardiovascular progenitors and primary Sca-
PCs—will be highly attractive to discriminate cardiogenic from 
angiogenic Crataegus components and elucidate their mode-of-
action on a molecular level. Since there is a growing agreement 
in the field that pre-existing cardiomyocytes likely represent the 
major contributors to de novo cardiomyocyte formation (Foglia 
and Poss, 2016), it will be important to further explore Crataegus 
extracts in the context of cardiomyocyte formation.
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